Karyopharm Therapeutics Inc.

NasdaqGS:KPTI Stock Report

Market Cap: US$79.6m

Karyopharm Therapeutics Management

Management criteria checks 3/4

Karyopharm Therapeutics' CEO is Richard Paulson, appointed in May 2021, has a tenure of 3.58 years. total yearly compensation is $2.63M, comprised of 28.2% salary and 71.8% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $212.26K. The average tenure of the management team and the board of directors is 2.9 years and 4.7 years respectively.

Key information

Richard Paulson

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage28.2%
CEO tenure3.6yrs
CEO ownership0.3%
Management average tenure2.9yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S

Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S

Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Apr 27
Benign Growth For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Underpins Stock's 28% Plummet

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17
Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

CEO Compensation Analysis

How has Richard Paulson's remuneration changed compared to Karyopharm Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$90m

Mar 31 2024n/an/a

-US$141m

Dec 31 2023US$3mUS$740k

-US$143m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$142m

Mar 31 2023n/an/a

-US$158m

Dec 31 2022US$7mUS$697k

-US$165m

Sep 30 2022n/an/a

-US$88m

Jun 30 2022n/an/a

-US$104m

Mar 31 2022n/an/a

-US$108m

Dec 31 2021US$8mUS$468k

-US$124m

Sep 30 2021n/an/a

-US$206m

Jun 30 2021n/an/a

-US$208m

Mar 31 2021n/an/a

-US$201m

Dec 31 2020US$1mn/a

-US$196m

Compensation vs Market: Richard's total compensation ($USD2.63M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.

CEO

Richard Paulson (57 yo)

3.6yrs

Tenure

US$2,626,288

Compensation

Mr. Richard A. Paulson, M.B.A. has been a Director of Karyopharm Therapeutics Inc. since February 26, 2020 and has been its Chief Executive Officer and President since May 3, 2021. Mr. Paulson has been an...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Paulson
President3.6yrsUS$2.63m0.27%
$ 212.3k
Sohanya Cheng
Executive VP3yrsUS$1.19m0.087%
$ 69.1k
Stuart Poulton
Executive VP & Chief Development Officer2.8yrsUS$1.11m0.032%
$ 25.5k
Reshma Rangwala
Executive VP2.7yrsUS$1.23m0.036%
$ 28.4k
Mansoor Mirza
Clinical Consultant14.9yrsUS$208.33k0%
$ 0
Sharon Shacham
Co-Founder & Chairman of Scientific Advisory Board16.9yrsUS$6.04mno data
Kristin Abate
VP, Chief Accounting Officerless than a yearno data0.042%
$ 33.2k
Brendan Strong
SVP of Investor Relations & Corporate Communicationsno datano datano data
Michael Mano
Senior VP4yrsUS$2.06m0.039%
$ 30.9k
James Accumanno
Chief Compliance Officer2.2yrsno datano data
Lisa DiPaolo
Executive VP & Chief Human Resource Officer2.3yrsno datano data
Brian Austad
Senior Vice President of Pharmaceutical Sciences6.8yrsno datano data

2.9yrs

Average Tenure

50.5yo

Average Age

Experienced Management: KPTI's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Paulson
President4.8yrsUS$2.63m0.27%
$ 212.3k
Mansoor Mirza
Clinical Consultant14.2yrsUS$208.33k0%
$ 0
Sharon Shacham
Co-Founder & Chairman of Scientific Advisory Boardno dataUS$6.04mno data
Chen Schor
Independent Director4.1yrsUS$128.33k0%
$ 0
Deepika Pakianathan
Independent Director11.7yrsUS$148.33k0%
$ 0
Garen Bohlin
Independent Director11.2yrsUS$138.33k0.036%
$ 28.7k
Barry Greene
Lead Independent Director11.9yrsUS$173.33k0.011%
$ 8.6k
Michael Savona
Member of Scientific Advisory Boardno datano datano data
Christy Oliger
Independent Director4.3yrsUS$138.33k0%
$ 0
Zhen Su
Independent Director1.3yrsUS$81.49k0%
$ 0
Andrew Kung
Member of Scientific Advisory Board4.6yrsno datano data
Andrew Lassman
Member of Scientific Advisory Board4.6yrsno datano data

4.7yrs

Average Tenure

57yo

Average Age

Experienced Board: KPTI's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Peter LawsonBarclays
Ying HuangBofA Global Research